Vol. 4 No. 9 (2024)
Reimbursement Reviews

Nivolumab (Opdivo)

decorative image of the issue cover

Published September 26, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nivolumab (Opdivo); strength: 40 mg nivolumab/4 mL (10 mg/mL) and 100 mg nivolumab/10 mL (10 mg/mL); route of administration: IV infusion.
  • Indication: Opdivo, as monotherapy, is indicated for the adjuvant treatment of adult patients with stage IIB or IIC melanoma following complete resection.